<DOC>
	<DOCNO>NCT00497471</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy weekly iron supplementation efficacy malaria chemoprophylaxis 2 12 month age infant live area intense perennial malaria transmission</brief_summary>
	<brief_title>RCT Iron Supplementation Malaria Chemoprophylaxis Prevention Severe Anemia Malaria Tanzanian Infants</brief_title>
	<detailed_description>411 Tanzanian infant randomly assign receive weekly malaria prophylaxis Deltaprimâ„¢ ( 3.125 mg pyrimethamine plus 25 mg dapsone ) placebo age 2-12 month . Children followed-up age 4 year . Uncomplicated febrile malaria , severe malaria anaemia morbidity assess hospital-based passive surveillance .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Born San Francis Designated District Hospital Ifakara Obvious severe congenital malformation : spina bifida , hydrocephalus anencepahlus Twins Birth weight &lt; 1,5 kg Clinical sign cerebral asphyxia Clinical sign neonatal congenital infection Mother unreliable ( deaf , mentally handicap )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Plasmodium Falciparum</keyword>
	<keyword>Antimlarial chemoprophylaxis</keyword>
	<keyword>Iron supplementation</keyword>
	<keyword>Tanzania</keyword>
</DOC>